| Literature DB >> 32296774 |
Martha E Sommer1,2, Jana Selent3, Jens Carlsson4, Chris De Graaf5, David E Gloriam6, Gyorgy M Keseru7, Mickey Kosloff8, Stefan Mordalski6,9, Aurelien Rizk10, Mette M Rosenkilde11, Eddy Sotelo12, Johanna K S Tiemann13,14, Andrew Tobin15, Nina Vardjan16,17, Maria Waldhoer10, Peter Kolb18.
Abstract
G protein-coupled receptors (GPCRs) are intensively studied due to their therapeutic potential as drug targets. Members of this large family of transmembrane receptor proteins mediate signal transduction in diverse cell types and play key roles in human physiology and health. In 2013 the research consortium GLISTEN (COST Action CM1207) was founded with the goal of harnessing the substantial growth in knowledge of GPCR structure and dynamics to push forward the development of molecular modulators of GPCR function. The success of GLISTEN, coupled with new findings and paradigm shifts in the field, led in 2019 to the creation of a related consortium called ERNEST (COST Action CA18133). ERNEST broadens focus to entire signaling cascades, based on emerging ideas of how complexity and specificity in signal transduction are not determined by receptor-ligand interactions alone. A holistic approach that unites the diverse data and perspectives of the research community into a single multidimensional map holds great promise for improved drug design and therapeutic targeting.Entities:
Year: 2020 PMID: 32296774 PMCID: PMC7155379 DOI: 10.1021/acsptsci.0c00024
Source DB: PubMed Journal: ACS Pharmacol Transl Sci ISSN: 2575-9108